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Autosomal dominant polycystic liver disease (ADPLD) is a distinct clinical and genetic entity that can occur
independently from autosomal dominant polycystic kidney disease (ADPKD). We previously studied two large
kindreds and reported localization of a gene for ADPLD to an ∼8-Mb region, flanked by markers D19S586/
D19S583 and D19S593/D19S579, on chromosome 19p13.2-13.1. Expansion of these kindreds and identification
of an additional family allowed us to define flanking markers CA267 and CA048 in an ∼3-Mb region containing
170 candidate genes. We used a combination of denaturing high-performance liquid chromatography (DHPLC)
heteroduplex analysis and direct sequencing to screen a panel of 15 unrelated affected individuals for mutations
in genes from this interval. We found sequence variations in a known gene, PRKCSH, that were not observed in
control individuals, that segregated with the disease haplotype, and that were predicted to be chain-terminating
mutations. In contrast to PKD1, PKD2, and PKHD1, PRKCSH encodes a previously described human protein
termed “protein kinase C substrate 80K-H” or “noncatalytic beta-subunit of glucosidase II.” This protein is highly
conserved, is expressed in all tissues tested, and contains a leader sequence, an LDLa domain, two EF-hand domains,
and a conserved C-terminal HDEL sequence. Its function may be dependent on calcium binding, and its putative
actions include the regulation of N-glycosylation of proteins and signal transduction via fibroblast growth-factor
receptor. In light of the focal nature of liver cysts in ADPLD, the apparent loss-of-function mutations in PRKCSH,
and the two-hit mechanism operational in dominant polycystic kidney disease, ADPLD may also occur by a two-
hit mechanism.
Introduction
Polycystic liver disease is characterized by the presence
of multiple bile duct–derived epithelial cysts scattered in
the liver parenchyma (Torres 1996). It often occurs in
association with autosomal dominant polycystic kidney
disease (ADPKD [MIM 173900 and MIM 173910]), but
it also exists as a distinct entity (ADPLD [MIM
174050]). Polycystic kidneys were detected in only one-
half of polycystic liver disease cases in old autopsy or
surgical series (Comfort et al. 1952; Melnick 1955). A
large and more recent retrospective study of medicolegal
autopsies in Finland also found that polycystic liver dis-
ease often occurs as an entity separate from ADPKD
(Karhunen and Tenhu 1986). Further evidence that
ADPLD is a novel inherited disease came from three
studies in which isolated ADPLD was excluded from
genetic linkage to the PKD1 or PKD2 loci for ADPKD
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(Somlo et al. 1995; Pirson et al. 1996; Iglesias et al.
1999). Finally, we recently identified a locus for ADPLD
on chromosome 19p13.2-13.1 (Reynolds et al. 2000).
ADPLD is characterized by an overgrowth of biliary
epithelium and supporting connective tissue (Torres
1996). As in polycystic liver disease associated with
ADPKD, the cysts derive from focal dilatations of small
clusters of intralobular bile ductules surrounded by fi-
brous tissue known as biliary microhamartomas (Ra-
mos et al. 1990; Qian et al. 2003). Some cysts in poly-
cystic liver disease derive by cystic dilatation of the
peribiliary glands that surround and communicate with
the large intrahepatic bile ducts (Kida et al. 1992; Qian
et al. 2003). Other lesions less consistently found in
polycystic livers include dilatation of the intrahepatic
and extrahepatic bile ducts and focal biliary fibroad-
enomatosis (Torres 1996). The latter are characterized
by fibrosis and enlargement of the portal tracts and
proliferation of the bile ducts.
ADPLD is often asymptomatic (Qian et al. 2003). As
a consequence, the disease may go undetected and is
likely to be underdiagnosed in the general population.
When symptoms occur, they are usually either due to
mass effects from the expanding cyst burden or due to
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hemorrhage, infection, or rupture of cysts. Liver met-
abolic and synthetic functions remain normal. Symp-
toms caused by the mass effect of the cysts include ab-
dominal distention, early satiety, dyspnea, and back
pain. Rarely, ascites can form because of hepatic venous
outflow obstruction by cysts, and lower extremity
edema can occur secondary to compression of the in-
ferior vena cava (Torres et al. 1994). Most patients with
polycystic liver disease require no treatment. In highly
symptomatic patients, percutaneous cyst aspiration and
sclerosis, cyst fenestration, partial hepatectomy, and
liver transplantation may be indicated. Determining fac-
tors regarding therapy include the extent, distribution,
and anatomy of the cysts, as well as the nature and
severity of the symptoms (Que et al. 1995).
Subsequent to our initial discovery of genetic linkage,
we narrowed the ADPLD candidate interval to ∼3 Mb
and focused our mutation screening efforts on ∼70
genes in the two-thirds of this interval that is conserved
in the mouse. We discovered heterozygous putative loss-
of-function mutations in PRKCSH, the gene encoding
a protein varyingly called “protein kinase C substrate
80K-H” or “the beta-subunit of glucosidase II.” The
protein is widely expressed in tissues and is highly con-
served as a single-copy gene in evolution from fission
yeast to man. The PRKCSH gene product is predicted
to be an endoplasmic reticulum luminal protein that
recycles from the Golgi. It is predicted to contain low-
density lipoprotein receptor domain class A (LDLa) and
EF-hand domains, suggesting that Ca2 binding may play
a role in its function. We report that PRKCSH functions
in cyst formation in lumen-forming epithelial tissues.
Subjects and Methods
Subjects
Blood samples for DNA analysis were obtained from
subjects belonging to 25 unrelated families with ADPLD
after they signed an informed written consent form, in
accordance with institutional review board–approved
protocols. Subjects from 19 families were specifically re-
cruited for this project and were studied at the General
Clinical Research Center of the Mayo Clinic (Qian et
al. 2003). Six additional patients were referred from
other centers. A panel of DNA samples from 15 of the
25 index cases was used for the initial screening for
mutations in candidate genes. All patients were evalu-
ated by abdominal ultrasonography, computed tomog-
raphy scan, or magnetic resonance scan. No patients—or
family members, when available—met the diagnostic cri-
teria for ADPKD (Ravine et al. 1994). Subjects aged40
years who had any liver cysts and those aged 140 years
who had at least four liver cysts were considered affected
(Reynolds et al. 2000).
Genotyping and Linkage Analysis
Genomic DNA was extracted from EDTA-treated
blood with the PureGene Kit (Gentra Systems). Linkage
analysis to the disease interval on chromosome 19 was
performed with 25 microsatellite markers between
D19S586 (32.94 cM) and D19S593 (45.5 cM) labeled
with HEX or FAM dye (table A1; fig. 1). PCR products
were separated by electrophoresis, using an ABI 3700
(Applied Biosystems), and were analyzed by Genescan
and Genotyper software (version 3.5; Applied Biosys-
tems). Allele calls by Genotyper were checked manually
for accuracy. Multipoint LOD scores were computed
using GENEHUNTER (version 2.1); two-point linkage
analysis used the MLINK (version 5.1) program of the
LINKAGE package. The ADPLD allele frequency in the
population was set at 0.0002, the phenocopy rate was
set to 0.01, and the heterozygous disease penetrance was
estimated to be 95%. Marker allele frequencies were set
to 1/n, where n is the number of alleles observed in the
pedigrees analyzed.
Identification of Candidate Genes
Genomic sequences were initially retrieved from the
Joint Genome Institute database. As genomic sequences
became available, each BAC and cosmid clone was an-
alyzed by RepeatMasker followed by gene prediction
programs GENSCAN and FGENES. BLAST analyses
against the GenBank nonredundant (nr) and EST
(dbEST) databases via the National Center for Biotech-
nology Information (NCBI) Web site were used to iden-
tify genes and ESTs mapping to the region of interest.
Candidate sequences were further annotated by searches
in a series of databases, including UniGene, PubMed,
and GenBank (on the NCBI Web site), as well as Celera.
Since the completion of the Human Genome Project
draft sequence, we have integrated the annotated ge-
nome resources from the Human Genome Mapviewer
[build 30] and Ensembl Genome Browser into our own
gene-prediction data.
Expression of transcripts in liver was confirmed by
RT-PCR. Poly-A RNA from human adult liver, kidney,
brain, and testis was obtained from Clontech and cDNA
was synthesized by use of the SUPERSCRIPT Pream-
plification System for First Strand cDNA Synthesis (In-
vitrogen). RT-PCR was performed by use of primer-spe-
cific reaction conditions.
Mutation Screening
Primers were designed using the program Primer 3,
on the basis of the annotated genomic sequence across
each exon, including regions of at least 20–40 bp of
flanking intervening sequence. A list of candidate genes
screened is provided in table A2. The primers for
Figure 1 Refinement of the genetic interval for ADPLD. A, Partial representation of the previously published family 1 (Reynolds et al.
2000), showing the disease-associated haplotype (black bar) and critical recombination events in newly recruited individuals (red boxes). Family
7 is a newly ascertained kindred with possible linkage and a centromeric recombination. B, Schematic representation of the disease-associated
haplotypes (all red) in two large kindreds (Reynolds et al. 2000) and family 7, along with critical recombinant chromosomes that define the
closest flanking markers (red boxes). Individual identifications correspond to previously published pedigrees for families 1 and 2 (Reynolds et
al. 2000).
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PRKCSH are given in table A3. In case of exons 1400
bp in size, overlapping primer pairs were designed to
keep amplicons !400 bp in size. PCR was performed in
30-ml reaction volumes using a GeneAmp PCR System
9700 (PE Applied Biosystems). The PCR mixture con-
tained 50 ng DNA, 5 mmol/l of each dNTP (Boehringer
Mannheim), 1 U of AmpliTaq DNA Polymerase (PE Ap-
plied Biosystems) and 5 pmol of each sense and antisense
primer in a reaction buffer (0.5 mmol MgCl2, 10 mmol
Tris-HCl pH 8.3, 50 mmol KCl). Reactions were first
heated at 95C for 3 min, followed by 35 cycles of PCR
amplifications (at 95C for 30 s, 60C for 30 s, and 72C
for 30 s). PCR products were directly analyzed by de-
naturing high-performance liquid chromatography
(DHPLC) on The Wave DNA Fragment Analysis System
(Transgenomic). The reference sequences of the ampli-
cons (wild-type DNA) are imported to the WAVEMaker
software version 3.3 (and, subsequently, version 4.1), to
generate a method that gives sequence-specific separa-
tion temperature and separation gradient for the ana-
lyzed DNA fragment. Eight to 12 ml of each PCR re-
action was injected onto the column and was eluted with
a linear gradient at a flow rate of 0.9 ml/min. The mobile
phase consisted of a mixture of buffer A (0.1 M TEAA
and 1 mM EDTA) and buffer B (25% acetonitrile in 0.1
M TEAA). If the resolution of the DHPLC profiles was
not adequate, a second temperature—typically 2C
above or below the first—was used to improve the res-
olution. Samples displaying altered elution properties
were sequenced bidirectionally using Big Dye Terminator
Cycle Sequencing Reactions on an ABI 3700 (PE Applied
Biosystems). Sequence electropherograms were com-
pared with gene sequence from GenBank and control
samples. Variants identified were tested in 20 normal
control subjects; if not present, an additional 66 normal
control subjects (total 86 samples, 172 chromosomes)
were tested, as well as segregation among family mem-
bers, if available.
Expression Analysis
A 386-bp RT-PCR product from exons 10–13 of
PRKCSH was 32P-labeled using the multiprime method
and was hybridized to an adult human MTN blot (Clon-
tech), as described elsewhere (Onuchic et al. 2002). The
putative splice-site variant in family 1 was examined
by RT-PCR from mRNA extracted from Epstein-
Barr–transformed lymphoblasts of an affected individual
in family 1. Primers spanning exons 2–17 of PRKCSH
amplified the entire ORF (table A3). Direct sequencing
in the reverse direction showed skipping of exon 16.
Results
We had previously studied two large kindreds and re-
ported localization of a gene for ADPLD without kidney
cysts to an ∼8-Mb region flanked by markers D19S586/
D19S583 and D19S593/D19S579 on chromosome
19p13.2-13.1 (Reynolds et al. 2000). As the next step
in the identification of the underlying gene defect, we
refined the genetic interval by fine genetic mapping and
by identification of additional disease chromosomes with
informative recombination events. For fine mapping, we
used the available genomic sequence in the region to
identify additional microsatellite markers (table A1). Us-
ing the previously reported recombinant chromosomes,
we were able to refine the interval to ∼5 Mb flanked by
CA802 and CA387 (fig. 1). Recruitment of additional
members of family 1 (II:17, III:20, IV:5, and IV:6) per-
mitted further refinement of the ADPLD interval, to ∼3
Mb flanked by CA267 and CA048 (fig. 1). The closest
flanking centromeric marker (CA048) was also sup-
ported by a recombination event, in the newly identified
family 7, that showed possible linkage to chromosome
19 (multipoint ) (fig. 1).Z p 1.12max
This region of the human genome is very gene rich
and did not present any particularly enticing positional
candidates on the basis of known structures or functions
of polycystin-1 and -2 (fig. 2). To aid in disease-gene
identification, we divided the ADPLD genomic region
conceptually into three general regions, each ∼1 Mb in
length. The telomeric portion, bounded by CA267 and
the acid phosphatase 5 gene (ACP5), is syntenic with
mouse chromosome 9 and contains ∼25 known genes
and ∼10 unknown predicted genes (fig. 2). The cen-
tromeric portion, flanked by D19S221 and CA048, is
syntenic with mouse chromosome 8 and also contains
∼25 known genes and ∼10 unknown predicted genes
(fig. 2). The middle of the interval, ∼1 Mb between
ACP5 and D19S221 is not conserved in mouse and
contains a large cluster of zinc finger genes (Bellefroid
et al. 1995). The latter region was excluded from mu-
tation detection, because we hypothesized that—as is
the case with ADPKD (Wu et al. 1998)—the liver cystic
pathway in ADPLD will be conserved in mice. In the
remainder of the region, we excluded genes from initial
mutation detection on the basis of any of the following
criteria: (1) the absence of transcript detected by RT-
PCR in liver tissue (CNN1, KLF1), (2) that the gene is
known to be mutated in another disease (LDLR,
EPOR, MAN2B1, CACNA1A), (3) mouse knockout
with no liver phenotype (CDKN2D, SMARCA4), (4)
genes encoding ribosomal proteins (RPSL30, RPSL18),
or (5) enzymes (RNASEH1, TGT, DNASE2, GCDH,
FARSL). We sought candidate genes expressed exclu-
sively in liver by screening liver, kidney, brain, and testis
cDNA by RT-PCR, but none were found. Although fam-
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Figure 2 Positional cloning strategy for ADPLD. A, Genetic map position for microsatellite markers used in linkage mapping. Sex-averaged
genetic distances (in cM), from the Marshfield map, are shown. B, Physical map of critical interval, showing newly identified markers including
the closest flanking microsatellites CA267 and CA048 (bold). C, Partial representation of known genes and their direction of transcription
(arrows). ZNF gene region, ∼1 Mb containing zinc finger genes, that is not conserved in the mouse genome. D, Genomic organization of
PRKCSH; exons indicated by vertical bars.
Table 1
Mutations in PRKCSH in Patients with ADPLD
Family Exon Nucleotide Changea ORF Changeb
No. of Affected
Individualsb
25 4 216insA N72Xfs84 2
41 9 IVS92TrC Splice site 1
O-1 13 1168insC I390Xfs400 1
2 14 1237CrT Q413X 16
7 15 1266CrG Y422X 3
1 IVS16 IVS161delGT Exon 16 skip; G446Xfs457 13
a Nomenclature for description of sequence variations is from the Leiden Muscular Dystrophy
Pages Web site. None of these variants were observed in 172 normal chromosomes.
b Number of affected individuals in the respective families—all variants segregated with the disease
haplotype where the haplotype could be established.
ilies 1 and 2 were not known to be related (Reynolds
et al. 2000), we tested for a possible founder mutation
by haplotype segregation analysis, in an effort to extract
additional genetic information to narrow the candidate
region. Informative sequence variants, SNPs, and small
insertion/deletion polymorphisms discovered during
mutation detection were analyzed by direct sequencing
and were tested by segregation. No common haplotype
was observed.
Our mutation screening panel consisted of 15 unre-
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Figure 3 Mutations in PRKCSH in ADPLD. A, Sequence electropherograms showing mutant (affected) and wild-type (control) sequences.
All template DNA was genomic except as indicated for the IVS161delGT mutation where both genomic (left) and RT-PCR (right) was analyzed.
Six mutations are shown. B, Segregation of mutations in families 1 (IVS161delGT), 2 (C1237T), and 7 (C1266G), as analyzed by DHPLC.
Only selected traces are shown, but the entire family was analyzed. Individual identifications correspond to previously published pedigrees
(Reynolds et al. 2000) and figure 1.
lated affected individuals. Of these, 10 were members
of families with at least one other affected member. Al-
though some of the families were large, our ability to
determine genetic linkage was hampered by the late on-
set of the disease—clinical diagnosis of ADPLD cannot
be excluded in individuals under age 40 years, partic-
ularly not in men (Qian et al. 2003). To compensate
for the lack of a large number of individuals with proven
linkage to chromosome 19, mutation detection was car-
ried out by a bipartite strategy (table A2). Mutation
screening by DHPLC heteroduplex analysis was carried
out in 15 unrelated affected individuals. In parallel, mu-
tation detection by direct sequencing was performed in
one affected individual from each of the three families
with proven or suggestive linkage (families 1, 2 and 7).
We chose to screen known genes in the region first (table
A2).
We detected sequence variations in PRKCSH by
DHPLC and sequencing that were not observed in 86
normal control individuals (172 chromosomes) and that
segregated with the disease haplotype, when it was
known (table 1; fig. 3). In addition, we observed several
intragenic polymorphisms (table A4). PRKCSH is an
∼15-kb gene encoded in 18 exons, of which the first
and last are untranslated (fig. 2). The predicted effect
of all of the pathogenic sequence variants we found is
premature termination of translation. The mutations
occur throughout the gene, from exon 4 to exon 16.
The mutation in family 1 (Reynolds et al. 2000) results
in deletion of the 5′ splice site in IVS16. We tested the
effect of this mutation on the PRKCSH transcript in
patient lymphoblasts by RT-PCR. We found skipping
of exon 16 in a transcript in which exon 15 is spliced
to exon 17, causing a frame shift and premature ter-
mination (fig. 3A). This mutation segregates on the af-
fected haplotype in family 1 (fig. 3B). The mutation in
family 2 (Reynolds et al. 2000) is a nucleotide substi-
tution 1237CrT resulting in a premature termination
codon, Q413X (fig. 3A). This mutation segregates with
the affected haplotype (fig. 3B). The mutation in family
7 is also nucleotide substitution producing a stop codon
that segregates in all affected individuals (fig. 3). Two
families (25 and O-1) have single-nucleotide insertions
in exons 4 and 13, respectively, that are predicted to
result in premature terminations after frame shifts (fig.
3). The mutation in family 41 is predicted to disrupt
the 5′ splice site in IVS9 (table 1; fig. 3). The most likely
result of all of these mutations is loss of PRKCSH
function.
The tissue-expression pattern of PRKCSH has not
been reported. A 2.5–3.0-kb transcript for this gene is
expressed in all tissues tested (fig. 4). In addition, cardiac
muscle seems to have a slightly larger transcript (∼3.0
kb) and skeletal muscle has a 7.0–7.5-kb transcript that
is detected even at high stringency (fig. 4). PRKCSH is
predicted to encode a 527–amino acid protein that is
very highly conserved (fig. 4), even in Schizosaccharo-
myces pombe and Arabidopsis thaliana (data not
shown). Structural features predicted by SMART and
PFAM analysis include a leader sequence, and cysteine-
rich LDLa type domain and one or two EF-hand do-
mains. The latter two domains likely confer Ca2 depen-
dent regulation on the PRKCSH product. The terminal
HDEL endoplasmic reticulum retention sequence is con-
served throughout evolution (fig. 4). Mutations in
PRKCSH cause ADPLD linked to chromosome 19p.
Discussion
We have identified PRKCSH as the gene responsible for
ADPLD by positional cloning. In contrast to the poly-
cystic kidney disease genes PKD1, PKD2, and PKHD1,
PRKCSH encodes a previously described human protein
called either “protein kinase C substrate 80K-H” (80K-
H) or “beta-subunit of glucosidase II” (GIIb). Similar to
the other polycystic disease proteins, however, its func-
tion remains incompletely understood. The mutations
found in patients with ADPLD are all predicted to cause
premature chain termination. Although most occur in
COOH-terminal exons 13–16, we also found mutations
in exons 4 and 9 in the NH2-terminus half of the protein.
In light of the nature and distribution of these mutations,
it is most likely that they constitute loss-of-function
changes, although, in the absence of functional studies,
dominant negative or gain-of-function/loss-of-regulation
effects in the residual protein products cannot be ex-
cluded. A common feature of all truncating mutations
in 80K-H/GIIb is the loss of the highly conserved ter-
minal four amino acids, His-Asp-Glu-Leu (HDEL). This
motif constitutes an endoplasmic reticulum (ER) luminal
retention sequence (Trombetta et al. 1996; Arendt and
Ostergaard 2000), and its loss presumably would result
in failure to retain 80K-H/GIIb in the ER. This would
be significant, because the protein has a leader sequence
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Figure 4 Expression and conservation of PRKCSH. A, Tissue northern showing expression of PRKCSH in all tissues including liver and
kidney. The transcript size is ∼2.5-3.0 kb with skeletal muscle showing evidence of a transcript 17.0 kb and cardiac muscle perhaps having a
pair of transcripts in the 2.5-3.0 kb range. B, High degree of sequence conservation from C. elegans to humans. S. pombe and A. thaliana also
have highly conserved PRKCSH homologs (not shown).
and no membrane spans suggesting that without reten-
tion by HDEL-mediated binding to the KDEL receptor,
it would enter the secretory pathway and be trafficked
out of the cell (Arendt and Ostergaard 2000). There is
precedent for reconciling loss-of-function changes with
dominant inheritance in polycystic liver and kidney dis-
ease. Liver and kidney cyst formation can occur by a
two-hit somatic mutation mechanism resulting in ho-
mozygous inactivation of PKD1 or PKD2 at the cellular
level (Watnick et al. 1998; Wu et al. 1998). This mech-
anism has been invoked to explain the focal nature of
cyst formation in affected organs but may not be the
only factor determining the occurrence of cysts. Evidence
exists for a potential role of compound heterozygous
states and gene dosage (high or low) in cyst formation
in ADPKD as well. However, given the similarity of the
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clinical presentations of liver disease in ADPLD and
ADPKD, the two-hit hypothesis is extensible to ADPLD
and bears further investigation.
The available functional data do not immediately sug-
gest role for PRKCSH in a common pathway with the
other polycystic disease genes, but the similarities in the
liver phenotype warrant consideration of such a con-
vergence of pathways. PRKCSH is broadly expressed
in tissues including those with lumen-forming epithelia
(e.g., liver, kidney, and pancreas). However, cyst for-
mation is confined to the liver, suggesting that there may
be tissue-specific factors required for cyst formation due
to mutations in this gene. The 80K-H/GIIb protein was
initially identified during a search for protein kinase C
substrates (Hirai and Shimizu 1990). Although 80K-H
turned out to be a poor substrate for PKC, other pos-
sible functions were later suggested by its ability to bind
advanced glycation end products (Li et al. 1996; Thor-
nalley 1998) and by its rapid phosphorylation following
activation of fibroblast growth-factor receptors (Shaoul
et al. 1995; Goh et al. 1996; Kanai et al. 1997). More
recently, homologous proteins were identified as the
beta subunit of glucosidase II (GIIb) (Trombetta et al.
1996; Arendt and Ostergaard 1997) and as a vacuolar
system-associated protein-60 (VASAP-60) (Brule et al.
2000).
80K-H/GIIb is an alternatively spliced protein that
migrates as a doublet at ∼80 kDa on polyacrylamide
gels (Arendt and Ostergaard 2000; Trombetta et al.
2001). It contains an NH2-terminal cysteine-rich LDLa
region, two EF-hand domains, a highly acidic domain
flanked by proline-rich segments presenting putative
Grb2-binding domains, and the aforementioned HDEL
endoplasmic reticulum luminal retention sequence
(Arendt and Ostergaard 2000; Trombetta et al. 2001).
An alternatively spliced region and two interaction do-
mains responsible for the heterodimerization with the
alpha catalytic subunit of glucosidase II (GIIa) have
been described in the mouse GIIb (Arendt and Oster-
gaard 2000). The overall domain structure of 80K-H/
GIIb suggests that it may be regulated by Ca2 bind-
ing—the LDAa, EF-hand, and acidic regions are all
potential Ca2 interacting motifs. Interestingly, among
the other polycystic disease gene products, polycystin-
1 contains an LDLa motif in its extracellular portion
and polycystin-2 is a Ca2 channel and has an EF-hand
in its COOH terminus.
GIIb does not have enzymatic activity, but it is es-
sential for the maturation of GIIa and its retention in
the endoplasmic reticulum (D’Alessio et al. 1999; Treml
et al. 2000). Glucosidase II plays a major role in reg-
ulation of proper folding and maturation of glycopro-
teins (Ellgaard et al. 1999). A preliminary step to protein
N-glycosylation is the sequential addition of N-acetyl-
glucosamine, mannose, and glucose to a dolichol py-
rophosphate lipid carrier to form a mature oligosac-
charide composed of two glucosamines, nine mannoses,
and three glucoses (Freeze 1998). This preassembled
oligosaccharide is transferred to an N-X-S/T sequence
in a nascent polypeptide chain in the ER. Cleavage of
the terminal glucose by glucosidase I and of the middle
glucose by glucosidase II generates a monoglucosylated
product (Ellgaard et al. 1999). This product is recog-
nized by the chaperones calnexin and calreticulin and
forms a complex with Erp57, a thiol reductase necessary
for proper protein folding. By chance, calreticulin also
maps to the ADPLD candidate region and was excluded
by mutation detection (fig. 2; table A2). It is conceivable
that alterations in the folding and maturation of specific
glycoproteins results in the development of biliary cysts.
Polycystin-1, polycystin-2, and fibrocystin/polyductin
are all glycoproteins. It has been suggested that the po-
lycystin-1/2 complex forms in the ER (Newby et al.
2002) and polycystin-2 is largely retained in the ER
membrane (Cai et al. 1999) and only selectively traf-
ficked to the primary cilia (Pazour et al. 2002). Improper
association and trafficking of polycystins due to defec-
tive glycosylation with mutant GIIb may tie ADPLD
into the ADPKD pathway. Direct or indirect interaction
of GIIb with the polycystins can also be considered.
Since 80K-H/GIIb is an ER luminal protein, it could
interact with the extracellular domains of either poly-
cystin. Interestingly, autosomal recessive carbohydrate-
deficient glycoprotein syndrome type Ib is associated
with congenital hepatic fibrosis and results from nearly
complete absence of phosphomannose isomerase, the
enzyme needed to maintain the dolichol pyrophosphate-
oligosaccharide pool (Jaeken et al. 1998; Niehues et al.
1998; Westphal et al. 2001). Understanding how mu-
tations in PRKCSH lead to cyst formation in the liver
and why they do not appear to affect the kidney will
prove instructive in understanding all human polycystic
diseases.
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Appendix A
Table A1
Primer Sequences for New Microsatellite Markers
MARKER
POSITION
IN BUILD
30
(bp)
PRIMER
Tm
(C)
PRODUCT
SIZE
(bp)Forward Reverse
CA802 9950900 ACTCTGGCAAACAACTTACAGAT CCTTAATCCTGGCTCCCTTC 60 152–170
CA267 10693500 TGCCCTTGGACACAAACATA GAGGGTGGATCAAGCATCTG 60 170–186
CA569 11036500 TGCTATGTGCTCATTGTAAACAG CATGGATGTCTGTCTACAAG 58 160–186
CAB2 11195400 ATTACAGGAATGAGCCACCAC ATGCAAACCTACATAGGAAGC 60 143–157
CA315 13059000 CGGGTTTCTCCATACTGGTC GCAAAATAGGAAGTCCCTGTC 60 164–174
CAF1 13230400 TTCTTCCCATTGCAGTTGTG ACACATCCTCATTCAAAGTTC 60 106–118
CA246 13656000 AGTTCTGCGTGGAATTGGAAG CAGAGAGCAGTGTGTGGACAA 58 139–149
CA048 13850000 TGTGGACTAGAGATGGAGCT GCTGATTTATGTGTCATTTCTCC 60 141–155
CA917 14290000 TTGGTCTCAAATTCCTGGCC GCTCTTACAGGCTGTTCTTC 60 148–170
CA665 14694900 GGTTCATTTTCTGCCTGGGG GACCAGCAATTCCCCAATTCC 58 191–205
CA387 15057620 CCAGGTCTTGTCCCTCCTAC TCTTCCGTGTGTGAATCCAA 60 172–198
CA262A 15194650 AGCTGTCCCAAAGCTGAGTC CACACAGACCAGCACACAAA 60 162–178
CA327 15256650 CCAGCAGGAAAGCACAATAA AGAGCCACATGGTGGAAACT 60 145–169
CA663B 15676310 CCCATTCAGAAATAACCTAGTCAC GCCAAGATTGTGCCACTGTA 60 163–179
CA699 16016000 ATTGAACTTGGCCTTGAGGA AAGGGAGAGGGAGCGTATGT 60 144–158
CA255 17656190 CGCAAGTCAATGCTTTTTGA ATGATTGCACCACTGTACGC 60 174–188
Table A2
Candidate Genes Excluded by DHPLC and Direct Sequencing
Gene Name Gene Locus DHPLCa Sequencingb
PDE4A Phosphodiesterase 4A, cAMP-specific 5141 
EDG8 Endothelial differentiation, sphingolipid G-protein-coupled receptor, 8 53637 
MGC15906 Hypothetical protein MGC15906 84971 
AK023011 Hypothetical protein FLJ12949 65095 
AP1M2 Adaptor-related protein complex 1, mu 2 subunit 10053 
CTL2 CTL2 57153 
ILF3 (NF90) Interleukin enhancer binding factor 3 3609 
DNM2 Dynamin 2 1785 
KIAA1518 KIAA1518 protein 25959 
AW245557 EST AW245557 AW245557 
TM4B Tetraspanin TM4-B 26526  
KIAA1395 KIAA1395 protein 57572 
RAB3D Ras-related small GTP binding protein 3D 9545 
ELAV3 Hu antigen C 1995 
AK023117 Hypothetical protein FLJ13055 64748 
BE885128 EST BE995128 126074 
BC011875 Hypothetical protein DKFZp547J036 84241 
115950 Hypothetical protein BC016816 115950 
115948 (MGC20983) Hypothetical protein MGC20983 115948 
ECSIT Signaling intermediate in Toll pathway-evolutionarily conserved 51295 
MGC4549 (AK001171) Hypothetical protein MGC4549 84337 
PTD008 PTD008 protein 51398  
DHPS Deoxyhypusine synthase 1725 
MGC4238 Hypothetical protein MGC4238 84292 
ASNA1 ArsA arsenite transporter, ATP-binding, homolog 1 439 
VMD2L1 (AK000139) Vitelliform macular dystrophy 2-like protein 1 54831 
199695 LOC199695 199695 
MGC10870 Hypothetical protein MGC10870 84261 
(continued)
Table A2 (continued)
Gene Name Gene Locus DHPLCa Sequencingb
Hook 2 Hook2 protein 29911  
JUNB Jun B proto-oncogene 3726 
SAST Syntrophin associated serine/threonine kinase 22983 
CALR Calreticulin 811 
RAD23A RAD23 homolog A 5886 
NFIX Nuclear factor I/X (CCAAT-binding transcription factor) 4784 
LYL1 Lymphoblastic leukemia derived sequence 1 4066 
FLJ20244 Hypothetical protein FLJ20244 55621 
NAC1 Transcriptional repressor NAC1 112939 
STX10 Syntaxin 10 8677  
ETR101 Immediate early protein 9592 
NOTE.— denotes that the gene was excluded by this method.
a DHPLC was performed across all exons under two conditions in 15 affected, unrelated individuals.
b Direct sequencing of all exons in one affected individual from families 1, 2, and 7.
Table A3
PCR Primers Used for Mutation Detection in PRKCSH
EXON
OLIGONUCLEOTIDE
ANNEALING
TEMPERATURE
(C)
PRODUCT
SIZE
(bp)Sense Antisense
1a GTTCGCGGGCATTTTTCAGGAAC GATCTCCCCAATCCTGGCCA 60 480
2a CGGGAAACTGAGTCAAAAGG GTGAAGACACAGCGCATCTC 60 254
3a GGCACTGAGCAGTGTTCAATAA ATGGGAGGACAGAGGTGGTA 60 244
4a GTGATGGGAGGGGTACTGTC TCTGTGGATGGATGGGACAT 60 349
5a GTGATGGGAGGGGTACTGTC TCTGTGGATGGATGGGACAT 60 349
6a TTGCAAGCCCACACTATGAG GCAGACCTGGTGGATCCTAA 60 244
7a GCAGCATGATCAAAAACCTG AGCTGGTCTCTTGCCTTCTG 60 274
8a AAGGAGGATCTGGCTGGTTT GGGTGACAGAGGTGGCTTCT 60 205
9a CTCCCTAGAAGTCCCCAACC AGGTCCTGAAGCAAGTTCCA 60 240
10a CAACCACTCCAGCCCCTGGT CCAGGTGCCAGAACCAGAGG 61 390
11a GCAGGAGGGGCAGAGACACC CCAAGATACTGGGGCTTGTG 60 500
12a GCAGGAGGGGCAGAGACACC CCAAGATACTGGGGCTTGTG 60 500
13a CTGGGAGTCAAGGAGCAGTC ATGAGGGTATGGGAGCACAC 59 227
14a TTCCCCAACCATCAGGAAACTG AGACCCTCCTGTGTCTGTCG 60 260
15a TCCCCTGCCTTGCAGGCCT GTTCCCCAAC CCATATGTCCC 60 320
16a TCCCCTGCCTTGCAGGCCT GTTCCCCAAC CCATATGTCCC 60 320
17a GGTCCATCTTCCTCAGGGCC CGAGCACCCG TCTGCCCATC 60 320
18a CTGGTCAACTCCTGGCCTCA CACACCCCAGCAAAGCGAGG 60 480
10–13b HAF: ACAGACAGACGCCACCTCTT HAR: TGGACTCCTCCATGTCCTTC 60 386
2–17c F2: GTGAAGACACAGCGCATCTC 17R: GGTCCATCTTCCTCAGGGCC 60 1741
10–17c HAF: ACAGACAGACGCCACCTCTT Ex17R: GGTCCATCTTCCTCAGGGCC 60 893
1–4d F1: CTGCTGGACAAGAGGGGTGC SCHR3: GACCCGGTTGGAGGGGATATA 60 402
1–8d F1: CTGCTGGACAAGAGGGGTGC HBR: TGTCATCATCCAGCTCCTTG 60 800
1–11d F1: CTGCTGGACAAGAGGGGTGC HCR: CTCCTCCTCCTCCTCTGTGG 60 1077
1–13d F1: CTGCTGGACAAGAGGGGTGC HAR : TGGACTCCTCCATGTCCTTC 60 1290
2–4d F2: GTGAAGACACAGCGCATCTC SCHR3: GACCCGGTTGGAGGGGATATA 60 313
2–8d F2: GTGAAGACACAGCGCATCTC HBR: TGTCATCATCCAGCTCCTTG 60 711
2–11d F2: GTGAAGACACAGCGCATCTC HCR: CTCCTCCTCCTCCTCTGTGG 60 988
2–13d F2: GTGAAGACACAGCGCATCTC HAR : TGGACTCCTCCATGTCCTTC 60 1201
2–17d F2: GTGAAGACACAGCGCATCTC 17R: GGTCCATCTTCCTCAGGGCC 60 1741
a PCR primers and condition for exon-by-exon amplification and mutation detection by DHPLC and direct sequencing.
b RT-PCR for Northern probe.
c RT-PCR for IVS161delGT mutation.
d RT-PCR IVS26delTCC mutation.
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Table A4
Polymorphisms in PRKCSH
Exon Nucleotide Change ORF Change
2 IVS26delTCC No
2 IVS2-75CrT No
3 IVS3-7CrG No
5 IVS5-32ArC No
5 IVS5-36GrC No
6 IVS6-5CrT No
9 IVS976insG No
11 G871A A291T
11 956insGGA 319insE
18 C1769T No
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